Royalty Pharma plcRPRXNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -0.41% | +0.05% | +7.71% | +7.90% | +4.78% |
| Gross Profit Growth | -0.41% | +0.05% | +7.71% | +7.90% | +4.78% |
| EBITDA Growth | -47.69% | +1148.01% | -34.55% | -39.85% | +12.79% |
| Operating Income Growth | -41.02% | +0.00% | -22.19% | -41.89% | +7.43% |
| Net Income Growth | -57.88% | +4888.47% | -70.42% | -47.02% | +2.88% |
| EPS Growth | -68.24% | +5400.00% | -59.09% | -45.08% | +36.17% |
| EPS Diluted Growth | -57.27% | +5400.00% | -69.57% | -27.17% | +6.38% |
| Weighted Average Shares Growth | -0.45% | -2.93% | -6.10% | -3.17% | -3.16% |
| Weighted Average Shares Diluted Growth | -2.16% | -3.24% | -5.80% | -5.63% | -4.99% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -3.90% | -10.32% | -44.70% | -0.14% | +11.40% |
| Free Cash Flow Growth | -3.90% | -10.32% | -44.70% | -0.14% | +11.40% |
| Receivables Growth | +20.31% | +7.01% | +17.65% | +3470.03% | +3178.31% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +11.24% | +9.16% | +3.77% | +7.23% | +7.67% |
| Book Value per Share Growth | +6.92% | +6.01% | +4.38% | -3.57% | -3.72% |
| Debt Growth | +24.08% | +24.08% | +5.27% | +17.86% | +17.58% |
| R&D Expense Growth | +0.00% | +10000.00% | +60000.00% | +10000.00% | +10100.00% |
| SG&A Expenses Growth | +14.20% | +92.02% | +228.60% | +109.33% | +143.04% |